Ovarian Cancer

Global Ovarian Cancer Market Research Report 2021-2025

Wed, 08 Sep 2021 15:45:00 +0000

Ovarian cancer is the most lethal gynecologic cancer and overall a leading cause of cancer incidence and mortality worldwide. In the context of China-US trade war and global economic volatility and uncertainty, it will have a big influence on this market. Ovarian Cancer Report by Material, Application, and Geography – Global Forecast to 2025 is a professional and comprehensive research report on the world’s major regional market conditions, focusing on the main regions (North America, Europe and Asia-Pacific) and the main countries (United States, Germany, United Kingdom, Japan, South Korea and China). In this report, the global Ovarian Cancer market is valued at USD XX million in 2021 and is projected to reach USD XX million by the end of 2025, growing at a CAGR of XX% during the period 2021 to 2025. The report firstly introduced the Ovarian Cancer basics: definitions, classifications, applications and market overview; product specifications; manufacturing processes; cost structures, raw materials and so on. Then it analyzed the world’s main region market conditions, includi...

$3,200.00

Ovarian Cancer Treatment Drugs Markets in China

Wed, 12 May 2021 15:00:05 +0000

China's demand for Ovarian Cancer Treatment Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, import & export, consumer consumption and capital investment for over two decades. This new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2010, 2015 and 2020) and long-term forecasts through 2025 and 2030 are presented. Major producers in China are profiled. The primary and secondary research is done in China in order to access up-to-date government regulations, market information and industry data. Data were collected from the Chinese government publications, Chinese language newspapers and magazines, industry associations, local governments’ industry bureaus, industry publications, and our in-house databases. Intervi...

$4,000.00

Ovarian Cancer Treatment Drugs Industry Forecasts - China Focus

Wed, 12 May 2021 15:00:05 +0000

This study focuses on China’s Ovarian Cancer Treatment Drugs industry forecasts. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China’s society and economy. China is one of the world’s major producers for industrial and consumer products. Far outpacing other economies in the world, China is the world’s fastest growing market for the consumptions of goods and services. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, imports & exports, consumer consumption and capital investment for over two decades. Rapid consolidation between medium and large players is anticipated since the Chinese government has been encouraging industry consolidation with an effort to regulate the industry and to improve competitiveness in the world market. Although China has enjoyed the benefits of an expanding market for production and distribution, the industry is suffering from min...

$1,800.00

Ovarian Cancer Treatment Drugs Companies in China

Wed, 12 May 2021 15:00:05 +0000

This study focuses on China’s Ovarian Cancer Treatment Drugs industry assessments and company profiles. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China’s society and economy. China is one of the world’s major producers for industrial and consumer products. Far outpacing other economies in the world, China is the world’s fastest growing market for the consumptions of goods and services. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, imports & exports, consumer consumption and capital investment for over two decades. Rapid consolidation between medium and large players is anticipated since the Chinese government has been encouraging industry consolidation with an effort to regulate the industry and to improve competitiveness in the world market. Although China has enjoyed the benefits of an expanding market for production and distribution, the industr...

$1,800.00

Polycystic Ovarian Syndrome - Pipeline Review, H2 2019

Wed, 11 Dec 2019 11:38:48 +0000

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Polycystic Ovarian Syndrome - Pipeline Review, H2 2019, provides an overview of the Polycystic Ovarian Syndrome (Women's Health) pipeline landscape.

Polycystic ovary syndrome (PCOS) is a common hormonal disorder among women of reproductive age. Symptoms include menstrual abnormality, acne, thinning hair on the scalp, weight gain, excess androgen and polycystic ovaries. The main risk factor for polycystic ovary syndrome (PCOS) is a family history. Other factors include type 2 diabetes and heart disease. Treatment includes hormone therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Polycystic Ovarian Syndrome - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Polycystic Ovarian Syndrome (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule t...

$2,000.00

Ovarian Cancer - Pipeline Review, H2 2017

Thu, 18 Jan 2018 15:45:29 +0000

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ovarian Cancer - Pipeline Review, H2 2017, provides an overview of the Ovarian Cancer (Oncology) pipeline landscape.

Ovarian cancer is any cancerous growth that may occur in different parts of the ovary. The majority of ovarian cancers arise from the epithelium (outer lining) of the ovary. Signs and symptoms of ovarian cancer include pelvic discomfort or pain, indigestion, gas or nausea, changes in bowel habits, such as constipation, loss of appetite and low back pain. The predisposing factors include age and family history. Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ovarian Cancer - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Ovarian Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and m...

$2,500.00

Ovarian Cancer - Heat Map and Analysis

Fri, 28 Apr 2017 10:35:57 +0000

Summary

Ovarian Cancer (OC) is the fifth most common malignancy diagnosed in women, and the most common gynecological cancer, with an estimated 225,000 new cases diagnosed globally in 2008. Rates are particularly high in developed countries, and especially in Northern Europe. However, substantial improvements in the treatment of OC have been made in recent decades, through the introduction of platinum-based compounds, and improvements in surgery.

This has resulted in an increase in the percentage of patients that survive for five years, from approximately 20% in the 1970s, to the current rate of 45%. However, there have been no significant improvements in the treatment of the disease in recent years, with platinum-based compounds remaining the standard of care for first- and usually second-line treatment.

The differences between many of these products are relatively nuanced, and must be understood fully by companies seeking to position a novel drug in this market. This tabular heatmap framework, designed to provide an easily digestible summary of these ...

$2,000.00

Polycystic Ovarian Syndrome - Pipeline Review, H1 2017

Wed, 05 Apr 2017 15:52:18 +0000

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Polycystic Ovarian Syndrome – Pipeline Review, H1 2017, provides an overview of the Polycystic Ovarian Syndrome (Women's Health) pipeline landscape.

Polycystic ovary syndrome (PCOS) is a common hormonal disorder among women of reproductive age. Symptoms include menstrual abnormality, acne, thinning hair on the scalp, weight gain, excess androgen and polycystic ovaries. The main risk factor for polycystic ovary syndrome (PCOS) is a family history. Other factors include type 2 diabetes and heart disease. Treatment includes hormone therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Polycystic Ovarian Syndrome – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Polycystic Ovarian Syndrome (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecul...

$2,000.00

EpiCast Report: Ovarian Cancer - Epidemiology Forecast to 2025

Wed, 11 Jan 2017 15:23:53 +0000

Summary

Ovarian cancer (OC; International Classification of Diseases, Revision 10 [ICD-10] code: C56) and cancer of the fallopian tubes and other uterine adnexa (ICD-10: C57) are leading causes of cancer mortality in women. Cancer of the ovary, fallopian tubes, and other uterine adnexa are collectively referred to as OC throughout this report. In the US, the American Cancer Society reports that OC accounts for more deaths than any other cancer of the female reproductive system.

GlobalData epidemiologists forecast the diagnosed incident cases of OC in the 7MM, to increase from 68,804 cases in 2015 to 77,457 cases in 2025, at an Annual Growth Rate (AGR) of 1.26%. The US will have the highest number of diagnosed incident cases of OC in the 7MM throughout the forecast period. The five year diagnosed prevalent cases of OC are also expected to increase from 191,345 cases in 2015 to 218,905 cases in 2025, at an AGR of 1.44%. Additionally, in 2015, there were 191,345 five-year diagnosed prevalent cases of OC in the 7MM, which is expected to increase to 218,905 cases b...

$3,995.00

Ovarian Cancer Global Clinical Trials Review, H1, 2016

Thu, 23 Jun 2016 09:26:10 +0000

Summary

GlobalData's clinical trial report, “Ovarian Cancer Global Clinical Trials Review, H1, 2016" provides an overview of Ovarian Cancer clinical trials scenario. This report provides top line data relating to the clinical trials on Ovarian Cancer. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive ad...

$2,500.00